BMY241227C62000
- 0.01
- 0.000.00%
Bristol-Myers Squibb Newsroom
Bristol-Myers Squibb (BMY.US) TYK2 inhibitors have achieved the primary endpoints in two key phase 3 clinical trials.
Bristol-Myers Squibb (BMY.US) announced today the positive results of the POETYK PsA-1 and POETYK PsA-2 trials. These two key Phase 3 clinical trials evaluated the efficacy and safety of the tyrosine kinase 2 (TYK2) inhibitor Sotyktu (deucravacitinib) in adult patients with active psoriatic arthritis (PsA).
Schwab US Dividend Equity ETF Reverses In December: What's Going On?
Bristol Myers Squibb's Sotyktu Shows Results in Psoriatic Arthritis Trials
Express News | Bristol-Myers Squibb Co: Sotyktu Was Well-Tolerated and Demonstrated Safety Consistent With Established Profile
Express News | Bristol-Myers Squibb Co - Phase 3 Trials Met Primary Endpoint With Significant Acr20 Response
Express News | Bristol Myers Squibb Announces Positive Topline Results From Two Pivotal Phase 3 Trials Evaluating Sotyktu (Deucravacitinib) in Adults With Psoriatic Arthritis
Bristol Myers Squibb Wins EU Approval for New Colorectal Cancer Treatment
Express News | Bristol Myers Squibb Receives European Commission Approval for Opdivo® (Nivolumab) Plus Yervoy® (Ipilimumab) for the First-Line Treatment of Adult Patients With Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
J.P. Morgan Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Raises Target Price to $70
Your Healthcare Costs Are Soaring! US Spending Reached $5 Trillion In 2023 With Major Increase in Obesity and Diabetes Drugs, Hospital Services
Jim Cramer on Bristol-Myers Squibb (BMY): Why Schizophrenia Drug Cobenfy Could Change the Game
Express News | Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025
BioArctic Partners With Bristol Myers Squibb In Licensing Deal For PyroGlutamate-Amyloid-Beta Antibody Program
Express News | Fangzhou Inc and Bristol-Myers Squibb have joined forces in China to establish a strategic alliance to jointly promote Digital Health.
Unusual Options Activity: NVT, IDXX and Others Attract Market Bets, NVT V/OI Ratio Reaches 238.0
EST Dec 18th Morning Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
Insitro Receives $25M In Milestone Payments From Bristol Myers Squibb For Achievement Of Discovery Milestones And Selection Of First Novel Genetic Target For ALS
Insitro Receives $25 Million in Milestone Payments From Bristol Myers Squibb for the Achievement of Discovery Milestones and the Selection of First Novel Genetic Target for ALS
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers